Single Cell Technology

Executive Summary

Single Cell Technology (SCT) is a Cambridge-based biotechnology company that is redefining antibody discovery through its proprietary AbTheneum™ platform. Unlike conventional methods such as hybridoma or phage display, SCT's platform captures and analyzes comprehensive single-cell data to deliver high-quality, actionable antibody leads with greater speed and precision. The company targets the growing demand for novel therapeutic antibodies, positioning itself as a modern alternative to established discovery approaches. With a focus on quality and data richness, SCT aims to accelerate the drug development pipeline for partners and collaborators. As a private entity, SCT operates with limited public disclosures but has the potential to disrupt the antibody discovery market. The company's platform-driven approach could appeal to large pharmaceutical companies seeking to expand their biologics pipelines. Success will depend on forming strategic partnerships, demonstrating the platform's superiority in head-to-head comparisons, and securing funding to scale operations. If SCT can validate its technology with high-profile collaborators, it may emerge as a key player in the single-cell antibody discovery space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership utilizing AbTheneum platform40% success
• Q3 2026Publication of preclinical data showcasing platform performance in a leading journal60% success
• Q3 2026Completion of a Series B funding round to scale operations and expand team50% success